Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

BACKGROUND: Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. CONCLUSIONS: Dostarlimab plus carboplatin-paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer, with a substantial benefit in the dMMR-MSI-H population.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer.
• 2 METHODS: We conducted a phase 3, global, double-blind, randomized, placebo-controlled trial.
• 3 Eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer were randomly assigned in a 1:1 ratio to receive either dostarlimab (500 mg) or placebo, plus carboplatin (area under the concentration-time curve, 5 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area), every 3 weeks (six cycles), followed by dostarlimab (1000 mg) or placebo every 6 weeks for up to 3 years.

This work deepens our understanding of the fundamental laws governing the universe, from subatomic particles to cosmic structures.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: